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Abstract. Bryostatin, a potent agonist of protein kinase C
(PKC), when administered to Hermissenda was found to
affect acquisition of an associative learning paradigm. Low
bryostatin concentrations (0.1 to 0.5 ng/ml) enhanced mem-
ory acquisition, while concentrations higher than 1.0 ng/ml
down-regulated the pathway and no recall of the associative
training was exhibited. The extent of enhancement de-
pended upon the conditioning regime used and the memory
stage normally fostered by that regime. The effects of two
training events (TEs) with paired conditioned and uncondi-
tioned stimuli, which standardly evoked only short-term
memory (STM) lasting 7 min, were—when bryostatin was
added concurrently—enhanced to a long-term memory
(LTM) that lasted about 20 h. The effects of both 4- and
6-paired TEs (which by themselves did not generate LTM),
were also enhanced by bryostatin to induce a consolidated
memory (CM) that lasted at least 5 days. The standard
positive 9-TE regime typically produced a CM lasting at
least 6 days. Low concentrations of bryostatin (0.5 ng/ml)
elicited no demonstrable enhancement of CM from 9-TEs.
However, animals exposed to bryostatin concentrations
higher than 1.0 ng/ml exhibited no behavioral learning.
Sharp-electrode intracellular recordings of type-B photo-
receptors in the eyes from animals conditioned in vivo with
bryostatin revealed changes in input resistance and an en-
hanced long-lasting depolarization (LLD) in response to
light. Likewise, quantitative immunocytochemical measure-
ments using an antibody specific for the PKC-activated
Ca2/GTP-binding protein calexcitin showed enhanced an-
tibody labeling with bryostatin.
Animals exposed to the PKC inhibitor bisindolylmaleim-
ide-XI (Ro-32-0432) administered by immersion prior to
9-TE conditioning showed no training-induced changes
with or without bryostatin exposure. However, if animals
received bryostatin before Ro-32, the enhanced acquisition
and demonstrated recall still occurred. Therefore, pathways
responsible for the enhancement effects induced by bryo-
statin were putatively mediated by PKC.
Overall, the data indicated that PKC activation occurred
and calexcitin levels were raised during the acquisition
phases of associative conditioning and memory initiation,
and subsequently returned to baseline levels within 24 and
48 h, respectively. Therefore, the protracted recall measured
by the testing regime used was probably due to bryostatin-
induced changes during the acquisition and facilitated stor-
age of memory, and not necessarily to enhanced recall of the
stored memory when tested many days after training.
Introduction
Many aspects of memory and recall can be studied espe-
cially well in the nudibranch Hermissenda because the
temporal specificity of experimental effects can be deter-
mined within 2 or 3 min, and the process of long-term
memory consolidation occurs within 220 to 230 min after
conditioning (Epstein et al., 2000, 2004). It is therefore
possible to correlate behavior with specific electrophysio-
logical, neurochemical, and structural cytological changes
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(Alkon and Fuortes, 1972; Alkon, 1984; Crow, 1988, 2004;
Alkon and Nelson, 1990; Alkon et al., 1990, 1998; Kawai et
al., 2002; Nelson et al., 2003).
Previous studies have found that two training events
(TEs) result in short-term memory (STM) lasting less than
10 min (Epstein et al., 2000, 2004). In Aplysia, inhibitors of
CREB-2 enhance STM to long-term memory (LTM) that
lasts about 1 day (Bartsch et al., 1995; Carew, 1996).
However, in Hermissenda, nine TEs result in a long-term
consolidated memory (CM) that becomes established 220
min after training. This CM lasts at least 6 days (Epstein et
al., 2004). There is another distinct memory phase that lasts
about 1 day (designated as a subtype of LTM; Epstein et al.,
2004). This memory stage becomes established at 60 min
post-training, and evidence suggests that it is distinct from
the traditionally reported intermediate memory that is
formed from existing mRNA (Crow et al., 1999). STM does
not require protein synthesis, but both LTM and CM do.
Thus, we have been able to readily study the spectrum of
events that correlate with the establishment of these mem-
ory stages and the transitions between them by using selec-
tive transcription and translation inhibitors (Epstein et al.,
2000, 2004).
The enzyme protein kinase C (PKC) has long been im-
plicated in the establishment of associative learning and
memory in Hermissenda and other animal models (McPhie
et al., 1993; Sossin et al., 1994; Newton, 1995; Alkon et al.,
1998; Weeber et al., 2000; Sutton et al., 2004). In Hermis-
senda, the initial activation of voltage-dependent Ca2
channels and the entry of Ca2 into the photoreceptors
triggers PKC autophosphorylation and its translocation
from the cytosol to the plasma membrane. Those initial
steps subsequently result in the activation of the GTP/Ca2-
binding protein calexcitin, which then binds to the ryano-
dine receptors on the endoplasmic reticulum, triggering a
release of internal Ca2 (calcium-induced calcium release).
Concurrently, the binding of calexcitin to the plasma mem-
brane closes the rectifying K-channels. The resultant ef-
fect is a long-lasting depolarization (LLD) of the photore-
ceptors that persists for many minutes. This enhanced
excitability produces positive feedback that further en-
hances Ca2 elevation during memory consolidation (Alkon
et al., 1998). Using quantitative immunocytochemistry, we
have demonstrated a rise in calexcitin within the B-photo-
receptors with the establishment of CM, but not STM
(Kuzirian et al., 2001).
Like tumor-promoting phorbol esters, the drug bryosta-
tin-1, which does not promote tumors, is a potent activator
of PKC (Smith et al., 1985; Kiss et al., 1991; Pettit, 1991),
and is now being tested as an anti-cancer drug (Blackhall et
al., 2001). Bryostatin in conjunction with nerve growth
factor has been shown to promote the growth of neurites
(Burry, 1998). In addition, bryostatin in subnanomolar con-
centrations has been found to cause the selective transloca-
tion of the -isoform of PKC, and the enhanced secretion of
soluble amyloid precursor protein- (sAPP) by the en-
zyme -secretase. The production of sAPP has been re-
ported to enhance memory and delay or retard the onset of
Alzheimer’s disease (Etcheberrigarary et al., 2004). Re-
cently, Sun and Alkon (2005) reported that bryostatin en-
hanced spatial maze learning in rats. Kortmansky and
Schwartz (2003) reported that short-term exposure to bryo-
statin-1 activates PKC, whereas prolonged exposure pro-
motes significant PKC down-regulation. However, Alkon et
al. (2005) reported that pre-exposure to bryostatin on 2–3
successive days prior to associative training produced suf-
ficient protein translation that post-training administration
of the protein inhibitor anisomycin was completely ineffec-
tive. Under these conditions, typical STM was expanded
into CM lasting many days. It follows then, that conditions
in which PKC is activated and up-regulated should lead to
increased memory acquisition and recall; conversely, PKC
down-regulation should lead to inhibition of memory for-
mation or lack of recall. This down-regulation of PKC is
well known from other systems (Sonneman et al., 2004).
Thus, armed with the knowledge of PKC activation by
bryostatin and the known effects of phosphorylated PKC on
memory formation and recall in Hermissenda, a study was
undertaken to test the possibility that bryostatin could, de-
pending upon concentration, either promote or inhibit mem-
ory acquisition and retention in this model system. Prelim-
inary results of this study have been reported (Scioletti et
al., 2004).
Materials and Methods
Behavioral training
Individual Hermissenda were trained using a Pavlovian
conditioning regime adapted from Crow and Alkon (1974)
and Lederhendler et al. (1986); see Epstein et al. (2004) for
details. In brief, animals were placed in covered transparent
acrylic trays (16 lanes, each about 0.9 cm wide and deep,
and 15 cm long) and then dark-adapted in a closed 10–12
°C incubator for 10 min before training or testing. Pharma-
ceuticals used in the experiments were administered to the
animals by immersion. Working solutions were dissolved in
natural seawater (NSW) and introduced into the lanes con-
taining Hermissenda through Luer syringe hubs cemented
into the cover of the training tray. Training consisted of
exposing the animals to bright white light (650–700 Lux)
for 6 s (conditioned stimulus, CS) paired, after a 2-s delay,
with 4 s of vigorous orbital shaking of the training tray
(unconditioned stimulus, US). Animals responded to the
shaking by contracting lengthwise (conditioned response,
CR) (Epstein, 1997). This combination of CS/US stimuli
was designated a paired TE and was repeated, depending
upon the experiment, at 1-min intervals. Random training
events (RTEs) consisted of presenting the CS and US to
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animals totally independently and randomly within a max-
imum 2-min inter-stimulus repeat interval.
Testing for CM was typically done at 4 h using the CS
alone (4 replicates). Animal responses were recorded us-
ing a time-lapse VCR and a video camera placed below the
transparent training tray. Changes in animal length were
measured directly on the video monitor. Inter-millimeter
lengths were estimated at 0.3 mm (i.e., 12.7 or 13.3 mm
for animals measuring slightly smaller or larger, respec-
tively, than 13 mm). The measure of learning or memory
recall scored was the percentage by which the animal’s
length changed between light-on and light-off (typically
1%–4%). Contraction of the foot (i.e., shortening of the
body length) was deemed a positive CR (Lederhendler et
al., 1986). Elongation during locomotion (the normal pho-
topositive response to light) was considered evidence of
non-learning or non-recall. Results are presented as means
of % Length Change,  standard error of the mean (SEM).
All animals were measured for each of four CS-testing
replicates per experiment.
Experimental pharmacology, immunocytochemistry, and
electrophysiology
Experiments were first directed at ascertaining the effects
of bryostatin on Hermissenda memory acquisition and re-
call, to obtain dose and TE response curves. Bryostatin
(stock solution: 10.0 g/ml in DMSO) was added to the
seawater in the lanes of the training tray (exposure by
immersion) either prior to training at the start of the 10-min
dark-adaption period, or within 3 min post-training. Ani-
mals were trained with 2-, 4-, 6-, and the standard 9-paired
CS/US TEs, with and without exposure to different concen-
trations of bryostatin (0.1, 0.25, 0.5, and 1.0 ng/ml [0.113,
0.282, 0.57, 1.13 nM, respectively] diluted with buffered
seawater; 50 mM Tris, pH 8). Additionally, animals receiv-
ing random presentations of the CS/UC (4R-TEs) and naive
animals were tested with bryostatin for possible drug-in-
duced effects. For the majority of conditions, CS testing was
done at 240 min (the minimum time period to verify CM
formation). However, for 2-TEs that only generate STM,
animals were tested at 90 min, 240 min, and 24 h. To test the
efficacy of bryostatin on long-term retention following sub-
optimal training conditions, animals that had received either
4- or 6-TEs, with and without bryostatin exposure, were CS
tested at 4 h and then daily for up to 5 days. Positive control
animals were those trained with 9-TEs in NSW.
Memory recall in Hermissenda can be blocked by pre- or
post-training administration of the translation inhibitor ani-
somycin (Ramirez et al., 1998; Epstein et al., 2003). To test
for the possible range of bryostatin effects, including protein
synthesis necessary for memory formation and consolida-
tion, animals were conditioned with paired TEs with bryo-
statin (0.25 ng/ml) added prior to training (during dark
adaptation) followed by anisomycin (1.0 g/ml) adminis-
tered immediately post-training. Memory retention of this
group was then compared to that of animals receiving just
bryostatin or NSW alone. Conditioning with 2-TEs was
chosen because it was the most responsive and normally
generated only STM that lasted less than 10 min (7 min).
Bryostatin is a known activator of PKC, and PKC phos-
phorylation and translocation from the cytosol to the plasma
membrane is required for memory formation in Hermis-
senda. Therefore, a very specific PKC inhibitor, Ro-32
(Ro-32-0432 [bisindolylmaleimide-XI]; 40 nM/ml) and its
ineffective analog Bis-V (bisindolylmaleimide-V; 40 nM/
ml) (negative control) were used to test whether bryostatin
functioned through the modulation or activation of PKC.
Animals were conditioned using 6-paired TEs, and then CS
tested at 4 h as an indicator of CM. The pharmaceuticals
were administered immediately before the usual 10-min
dark-adaptation period preceding training. Ro-32 and bryo-
statin (0.25 ng/ml) were administered separately to animals:
one before the dark-adaptation period; the other immedi-
ately post-training. The sequence was then reversed to as-
certain if the effects of one could be counteracted by the
other, and to elucidate what the activation time domains
might be. NSW and Bis-V were used as negative controls,
while bryostatin alone applied before training served as the
positive control. The percent of change in animal length
(CR) was used as the measure of associative conditioning.
Behavioral measures were tested for significance using
nested analysis of variance (ANOVA), and paired Student t
test comparisons (n values consisted of means of length
changes/measure/CS-test replicate/animal/treatment).
As further verification that bryostatin was working
through activation of PKC, expression levels of the GTP/
Ca2-binding protein calexcitin were quantitatively ana-
lyzed immunocytochemically. Kuzirian et al. (1998, 2001,
2003) found an associative-conditioning-induced rise in ca-
lexcitin levels in the B-photoreceptors that persisted for up
to 24 h, and reported that this rise could be demonstrated by
antibody-labeling intensity measurements. Separate groups
of Hermissenda received associative conditioning using ei-
ther 4-random or 6-paired TEs in the presence or absence of
bryostatin (0.25 ng/ml, or only NSW, respectively; admin-
istered 10 min prior to training during dark-adaptation).
After each experimental treatment and CS testing regime,
animals were quickly removed from the training tray lanes
and decapitated. Their central nervous systems were fixed
(4% paraformaldehyde in Tris-buffered [20 mM] NSW),
followed by later processing for immunocytochemistry
(Kuzirian et al., 2001). In brief, the fixed central nervous
systems were washed, dehydrated, and embedded in poly-
ester wax, then sectioned at 4–6 m, labeled with a rabbit
polyclonal antibody to calexcitin (25U2), and finally reacted
with the chromogen amino-ethylcarbazole using microper-
oxidase (ABC method; Vector Laboratories, Burlingame,
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CA). Intensity (0–256 greyscale intensity) was measured
from digital photomicrographs of at three to five serial
images of each eye, using NIH Image ver. 1.36 or Image-J
software. Means (B-cell photoreceptor intensities minus
background; unstained neuropile regions) from each condi-
tion were tested for significance using nested ANOVA and
paired Student t test comparisons (n values consisted of
measures/serial-sections/block/animal/treatment).
Electrophysiological recordings were used to measure
some initial biophysical properties of the medial B-photo-
receptor’s light response following bryostatin treatment.
Animals were conditioned using training regimes of 4-, 6-,
and 9-TEs, with bryostatin treatment and NSW controls.
Over the subsequent 24–36 h, animals were sacrificed, the
CNS dissected, and sharp-electrode intracellular recordings
done for each experimental condition, following previously
described methods (Alkon, 1980; Alkon et al., 1982; Saka-
kibara et al., 1986, 1994). Specifically measured for each
B-photoreceptor was the duration of the conditioning in-
duced LLD, and the spike frequency generated by a single
light flash equal to that of the training conditions. These
parameters were compared for the number of training events
used, and the presence, or absence (NSW only), of bryosta-
tin. The means of the LLDs (in s) and spike frequencies
(number/s) were recorded and statistically compared using
ANOVA, including hierarchic and paired Student t test
comparisons between experimental conditions.
Results
Under control conditions used to test bryostatin for
possible non-associative conditioning effects in Hermis-
senda, there was no alteration of the expected typical
post-conditioning behavior. No excess mortality or overt
indications of toxic effects were observed. Bryostatin
applied to naive (non-trained) animals produced no CS-
induced unconditioned response (UCR; foot [body
length] contraction due to agitation). Bryostatin admin-
istered with random, suboptimal training regimes (fewer
than nine CS/US repetitions) also did not generate any
conditioned responses (CR). When the CS was presented,
all animals treated under non-learning conditions re-
sponded with an elongation in body length—that is, a
normal (untrained), positive phototaxis (Table 1). Thus,
no drug-induced, consolidated memory (CM) imitating
associative conditioning was initiated.
Dose-response results obtained from animals that expe-
rienced various associative training regimes (4-, 6-, 9-TEs)
indicated that subnanogram concentrations of bryostatin
(0.1 to 0.5 ng/ml) all produced CM lasting for days. Thus,
for animals dosed and trained under these conditions, pos-
itive results obtained with 4-h CS testing were a valid
indicator that CM had been established. Bryostatin at higher
doses (1.0 ng/ml), however, down-regulated the system,
and positive CR-results were not obtained (Table 2).
Two paired training events typically had initiated only
STM lasting less than 10 min. However, when bryostatin
(0.25, 0.5 ng/ml) was administered to animals during a
2-paired TE conditioning regime, CRs were still present at
20 h. There were no statistically different, dose-dependent
effects demonstrated at the low concentrations used: 0.25
and 0.5 ng/ml gave identical positive results at 90 and 240
min. However, as with 4-, 6-, and 9-TEs, bryostatin admin-
istered concurrently with 2-TEs at concentrations higher
than 1.0 ng/ml again demonstrated down-regulation of key
biochemical pathways; no positive CR results were obtained
with CS testing at 90 min or 4 h. Figures 1 and 2 display
results for the various paired training regimes with bryosta-
tin administered at 0.25 ng/ml with 4-h CS testing.
The anisomycin-bryostatin study confirmed the results
of other studies (Epstein et al., 2003; Alkon et al., 2005)
showing that protein synthesis is involved in memory
storage and its subsequent recall. Animals that had re-
ceived 2-paired TEs plus bryostatin (0.25 ng/ml) and then
were tested for recall at 4 h showed positive CRs with the
CS alone. However, for similarly treated animals also
exposed to anisomycin (1 g/ml) immediately following
training, no long-term memory was demonstrated; results
were statistically equal to those of NSW controls (Fig. 3).
Similar findings were obtained with animals conditioned
with 4- and 6-paired TEs; anisomycin administered im-
mediately after training gave no CRs when tested with
the CS, even if they had been pre-exposed to effective
memory-enhancing concentrations of bryostatin (results
not presented). Thus, protein synthesis was involved in
memory acquisition, in the transition from STM to CM,
or in both processes.
Table 1
Behavioral results of 4-h retention test for bryostatin administered to randomly trained and naive Hermissenda
Training events (TEs) Experimental conditions1 % Foot change SEM Measured differences Animals tested
Random: 4-TEs NSW 3.51 1.53 11 4
Bryo (0.25ng/ml) 2.62 0.81 38 11
Naı¨ve: 0-TEs Bryo (0.25ng/ml) 2.48 0.81 22 8
1 NSW, natural seawater; Bryo, bryostatin.
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PKC antagonist studies yielded the following information
(Fig. 4). As expected, Hermissenda treated with NSW and
the ineffective inhibitor analog Bis-V (bisindolylmaleim-
ide-V; 40 nM/ml), showed no CRs following associative
conditioning using 6-paired TEs and CS testing at 4 h.
Ro-32 (Ro-32-0432 [bisindolylmaleimide-XI]; 40 nM/ml),
a highly specific PKC inhibitor, was effective at preventing
retention recall only when administered during the paired
CS/US conditioning period and prior to bryostatin (0.25
Table 2
Results of behavioral test administered to bryostatin-treated Hermissenda under paired associative training conditions
Training events (TEs) Experimental conditions1 % Foot change SEM Measured differences Animals tested
4-h Retention Tests
Paired: 9 TEs NSW 2.76 0.65 33 9
Bryo (0.1 ng/ml) 1.60 0.56 16 4
Bryo (0.25 ng/ml) 2.99 0.91 59 16
Bryo (1.0 ng/ml) 2.23 0.86 35 10
Paired: 6 TEs NSW 3.06 1.358 16 4
Bryo (0.25 ng/ml) 1.98 0.87 15 4
Paired: 4 TEs NSW 1.97 0.69 38 12
Bryo (0.1 ng/ml) 1.61 0.56 16 4
Bryo (0.25 ng/ml) 2.89 0.91 62 19
90-min Retention Test
Paired: 2 TEs NSW 2.27 0.69 10 4
Bryo (0.25 ng/ml) 2.60 0.65 28 8
Bryo (0.5 ng/ml) 2.40 1.20 16 4
Bryo (1.0 ng/ml) 0.65 1.01 12 4
4-h Retention Test
Paired: 2 TEs NSW 3.24 2.03 11 4
Bryo (0.25 ng/ml) 1.49 1.05 26 7
Bryo (0.5 ng/ml) 2.46 1.47 14 4
Bryo (1.0 ng/ml) 1.65 0.98 14 4
1 NSW, natural seawater; Bryo, bryostatin.
Figure 1. Effects of bryostatin on behavioral training and retention.
Hermissenda receiving optimal (9) and suboptimal (2, 4, 6) paired
conditioned stimulus/unconditioned stimulus training events (TEs) were
tested for the conditioned response (CR) at 4 h. Negative values indicate
learning. When treated with bryostatin (0.25 ng/ml; applied during pre-
training, dark adaptation; 10 min), animals demonstrated positive learning
(conditioned-stimulus-induced conditioned response, CR; foot contrac-
tion). With 9-paired TE animals (optimal conditions), there were no sig-
nificant differences between bryostatin treatment and natural seawater
(NSW). However, animals receiving suboptimal TEs without bryostatin
(NSW) showed no CR, and foot elongation was as in normal locomotion.
(n  4–20 animals/treatment; ANOVA differences, P  0.01.)
Figure 2. Effects of bryostatin on long-term retention of consolidated
memory (CM). Animals were trained with suboptimal training regimes of
4- and 6-paired training events (TEs); with bryostatin (0.25 ng/ml) and
without (NSW [natural seawater] controls); 9-paired TEs and NSW (9TE/0
ng bryostatin) served as positive controls. All animals were tested with the
CS alone at 4, 24, 48, 72, and 96 h (for the 6TE/0.25 ng bryostatin animals,
the time was extended to 120 h). Animals trained suboptimally (non-
inducing conditions for CM) plus bryostatin all demonstrated CM retention
equal to the 9TE/0 ng control animals, thus indicating enhancement by
bryostatin to full development of CM. (n  12 animals/treatment; Stu-
dent’s t values/data point, t  2.0; P  0.05.)
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ng/ml) exposure. Animals trained similarly but with the
drugs applied in the opposite sequence (bryostatin exposure
during training preceding Ro-32 administration immedi-
ately post-training) and CS-tested at 4 h, showed positive
CRs, as did animals exposed to bryostatin alone (Fig. 4).
The 16-min exposure period to either drug (10-min dark-
adaption plus 6 min of training) was sufficient to allow the
full induction of each drug’s effect. Importantly, the effect
of the initial drug was unable to be canceled or overridden
by the other.
The immunocytochemical intensity studies designed to
elucidate whether bryostatin worked through PKC activa-
tion of calexcitin gave results consistent with the known
interactions of the photoreceptor second messenger system
(Alkon et al., 1998) and previously published results
(Kuzirian et al., 2001, 2003) (Fig. 5A). Conditioning with
4-random or 6-paired (CS/US) TEs produced statistically
similar immunolabeling intensities for calexcitin (greyscale
levels: 14.2  2.96; 17.5  2.34, respectively) in animals
Figure 5. (A) Immuno-intensity measurements (as 0–256 greyscale
intensities) of calexcitin antibody labeling in B-photoreceptors as a func-
tion of bryostatin and training regime. Animals experiencing random
conditioned stimulus/unconditioned stimulus training (4RTE-NSW) and
those receiving paired associative training (6PTE-NSW) in natural seawa-
ter (NSW) without bryostatin demonstrated base levels of calexcitin com-
parable to naive animals (Kuzirian et al., 2001, 2003). Bryostatin (0.25
ng/ml) administration increased calexcitin levels for both training para-
digms. The elevated calexcitin levels seen with 4-random TEs (4RTE-
0.25Bryo) (2 increase) were not accompanied by concurrent positive
testing responses and consolidated memory (CM) retention. However,
calexcitin levels increased 4.3 in animals receiving 6-paired TEs
(6PTE-0.25Bryo) plus bryostatin. These animals thus treated exhibited
conditioned responses and CM recall. (B) Behavioral responses of animals
trained and used for the calexcitin immunocytochemical intensity measures
(A). Only paired, 6-TEs training plus bryostatin produced positive learning
and demonstrated recall of CM. Labels on graph as described above. For A,
all Student’s t comparisons were significantly different (P  0.05 to
P 0.001) except the controls of 4- and 6-TEs without bryostatin.
Figure 3. Behavioral data indicated enhanced bryostatin (0.25 ng/ml)
effects on memory recall involved protein synthesis. Animals receiving
post-training administration of the mRNA translation inhibitor anisomycin
(1 g/ml) following 2-paired training events (TEs) and conditioned stim-
ulus testing at 4 h did not exhibit retention of enhanced consolidated
memory. (n  4 animals/treatment; ANOVA, P  0.01.)
Figure 4. Effects of bryostatin on consolidated memory (CM) under
control and antagonistic training conditions. Hermissenda received
6-paired conditioned stimulus/unconditioned stimulus training events
(TEs). Natural seawater (NSW) and Bis-V (bisindolylmaleimide-V; 40
nM/ml)-treated animals served as negative controls; CM was not evident
nor a positive conditioned response expressed when tested at 4 h. Animals
receiving bryostatin (Bryo; 0.25 ng/ml) alone or bryostatin applied before
training (during dark adaptation), followed by the PKC inhibitor Ro-32
(Ro-32-0432; bisindolylmaleimide-XI; 40 nM/ml) administered within 3
min post-training (Bryo-Ro32), exhibited retention of enhanced CM. How-
ever, Ro-32 applied pre-training followed by bryostatin at 3 min post-
training (asterisk; Ro32-Bryo) produced no conditioned response; animals
elongated in normal locomotion, indicating that CM formation was inhib-
ited. (ANOVA, P  0.01.)
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trained in NSW. As illustrated in Figure 5B, neither training
regime induced acquisition or retention of the conditioned
behavior (no recall demonstrated). Bryostatin (0.25 ng/ml)-
exposed animals given 4-RTEs showed a significant in-
crease in calexcitin levels (2 increase; greyscale level:
29.2  7.7) over animals kept in NSW. However, the
random training regime did not induce a positive CR in
those animals when tested for CM retention at 4 h. Hermis-
senda trained with 6-paired TEs plus bryostatin demon-
strated the positive CR as well as a greater than 4.3
increase in calexcitin levels (greyscale level: 74.4  7.3; an
intensity level within the statistical limits for calexcitin
levels from animals experiencing 9-paired TEs; data not
graphed). Analysis of the microscopic images used to obtain
the intensity measurements indicated that calexcitin immu-
nolabeling was confined to the B-photoreceptors. Neither of
the two A-type photoreceptors stained positively (Fig. 6A,
B). Additionally, a preliminary comparison of the staining
Figure 6. Photomicrographs of eyes illustrating the calexcitin immunocytochemistry of bryostatin-treated
and non-treated control (natural seawater, NSW) Hermissenda. Black arrows indicate B-photoreceptors, which
in the left-hand panels were highly immunolabeled in animals trained and exposed to bryostatin (0.25 ng/ml);
the photoreceptors in the right-hand panels (from NSW control animals) were significantly less stained. Blue
arrows in upper left panel indicate two stained photoreceptor axons.
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intensities of the three B-cells indicated that the medial
B-cell (photoreceptor located nearest the cerebropleural
ganglion) consistently labeled most intensely (data not pre-
sented).
Immunocytochemical intensity data from past experi-
ments conducted under identical cytological conditions
were compared and analyzed for any apparent trends (Table
3; Fig. 7). The analyses revealed that calexcitin immuno-
intensity measurements fell into four distinct groups. The
base level expressed for calexcitin had a greyscale intensity
level below 20 (mean level, 17.3  0.5). Grouped within
this level were naive animals, animals that had received
suboptimal training that did not generate acquisition of
associative conditioning or its retention, and 48-h post-
trained animals. A second category denoted an initial acti-
vation level (expressed greyscale levels between 30 and 35,
occurring between 5 and 30 min). This level of calexcitin
activation represented training conditions that produced
only STM, or was an intermediate, post-training level ex-
pressed in animals sampled during the ramp-up phase from
training regimes that eventually generated consolidated
memory. The third category, greyscale levels greater than
55, delineated full learning acquisition. It included animals
that had received paired, 9-TE training regimes as well as
animals given suboptimal numbers of paired training repli-
cates (4–6 TEs) augmented by bryostatin exposure. This
intensity level was attained within 40 min post-training with
9-paired TEs, and it was sustained for more than 200 min.
The last category represented a memory/retention-state
level (greyscale levels 27). Animals receiving 9-paired
TEs returned to this slightly-above-baseline calexcitin in-
tensity level within 240 min following training. Calexcitin
intensities were sustained at this level for more than 24 h,
but returned to baseline by 48 h post-training.
The initial electrophysiologic data obtained were consis-
tent with demonstrated behavioral results and known phys-
iology (Table 4; Fig. 8). Animals trained in NSW with 4-
and 6-paired (CS/US) TEs for these experiments did not
demonstrate retention of the CR at the 4-h test time (CS
alone) (data not graphed). For this group, the length of the
after-spike depolarizing wave measured in vitro was short
(23  2.48, 18.5  1.6 s, respectively; Fig. 8A). Animals
similarly trained but in the presence of bryostatin (0.25
ng/ml; administered during dark-adaption prior to training)
all tested positive for training acquisition and CM retention.
The B-photoreceptors of these animals exhibited an ex-
tended period of depolarization (long-lasting depolarization;
LLD) after light-induced spiking activity (Fig. 8B). The
duration of the bryostatin-induced LLDs for 4- and 6-paired
TEs were statistically similar to light-induced responses in
photoreceptors from animals experiencing 9-paired CS/US
training regimes with or without bryostatin being present (t
Table 3
Cumulative calexcitin (CE) immuno-intensity data illustrating the calexcitin activation levels obtained under different conditions of memory acquisition
and recall
Experimental conditions1 Greyscale (0 to 256) Intensity SEM Measured differences Animals tested
Base level: Non-acquisition; Non-retention state 17.33 0.50 145 49
CE-activation: STM acquisition; No long-term retention (4-h) 32.05 1.24 35 22
CE-activation: CM (24-h) acquisition/retention 61.38 2.34 109 47
Non-associative conditioned; bryostatin activation alone 57.90 3.45 14 6
CM: Long-term retention state 27.32 1.24 51 18
1 STM, short-term memory; CM, consolidated memory.
Figure 7. Cumulative data from calexcitin immunocytochemical stud-
ies depict the time course of calexcitin levels induced by various training
regimes and bryostatin administration. Base level (0 min) represents in-
tensity levels in naive, untrained animals, and those who had received
suboptimal, non-acquisition training conditions. Between 5 and 30 min,
calexcitin rose to this level in animals that demonstrated only short-term
memory. Maximal levels were obtained between 40 and 200 min in
animals that expressed full, long-term consolidated memory (CM) lasting
days, whether by paired, 9-TEs (training events) conditioning or paired
suboptimal TEs (4-, 6-TEs) plus bryostatin (0.25 ng/ml). This level was
also found in animals that had been randomly trained or in naive animals
receiving bryostatin only and tested with the conditioned stimulus at 240
min. Lower but sustained calexcitin levels lasting 4 to 24 h post-training
occurred in animals that develop full CM. All categories are significantly
different from each other (n  6–47 animals; Student’s t comparisons,
P  0.01).
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values 1.49, P  0.09; n  6 animals/treatment) (Fig.
8A). In addition, spike frequency analyses between the
experimental conditions matched the LLD results. The
mean spike frequencies were 2.75 times higher for the
bryostatin-treated, 4- and 6-paired TEs animals (Fig. 8B)
than for the NSW controls (ANOVA; n 17, F 208, P
0.05).
Discussion
The results described in this study concur well with the
known PKC physiology previously described for Hermis-
senda (Alkon et al., 1998) and the pharmacology of bryo-
statin (Smith et al., 1985; Burry, 1998; Kortmansky and
Schwartz, 2003). It has been well demonstrated in Hermis-
senda that associative-conditioning-induced Ca2 entry into
the B-photoreceptors initiates PKC activation and its auto-
phosphorylation (Farley and Auerbach, 1986; Alkon and
Nelson, 1990; Farley and Schuman, 1991; Alkon et al.,
1998; Crow et al., 1998; Crow, 2004). Similar PKC activa-
tion has been reported in other learning models, including
Aplysia and vertebrates (Bank et al., 1988; Scharenberg et
al., 1991; Sossin et al., 1994; Vianna et al., 2000; Weeber
et al., 2000; Abel and Lattal, 2001; Sutton et al., 2004). In
Hermissenda, this activation causes PKC to translocate to
the cell membrane (McPhie et al., 1993). Subsequently, this
translocation induces secondary pathway cascades that lead
to the activation and increased production of the GTP/Ca2-
binding protein calexcitin (Nelson et al., 1990, 1996, 1999;
Ascoli et al., 1997; Kuzirian et al., 2001), the release of
internal calcium from the endoplasmic reticulum, and the
reduction of outward K currents that triggers a rise in the
resting potential and the establishment of a long-lasting
depolarization. Early gene activation is also associated with
PKC up-regulation caused by these same associative con-
ditioning regimes (Alkon et al., 1998).
Bryostatin, a macrocyclic lactone, is a potent, specific
activator of PKC. It acts similarly to phorbol esters by
binding to the regulatory domain of PKC (Smith et al.,
1985; Singh et al., 1994; Burry, 1998) and causing in-
creased activity in membranes. In addition, both agents
activate signaling pathways that lead to increased transcrip-
tion and rapid early protein synthesis (Burry, 1998). Bryo-
statin has the advantages that it is not a tumor promoter and
it induces PKC activation in subnanomolar concentrations.
In addition to stimulating PKC-induced outgrowth of nerve
growth factor-dependent neurites (Burry, 1998), it favors the
generation of the nontoxic form of soluble -amyloid precur-
sor protein by differentially activating the isoform, PKC-
(Etcheberrigaray et al., 2004). Bryostatin has recently been
reported to enhance spatial maze learning in rats (Sun and
Alkon, 2005), and learning in rabbits experiencing tone and
nictitating membrane associative training paradigms (as re-
ported in Alkon et al., 2005). Its effects can be readily inhibited
by many bisindolymaleimide compounds (Burry, 1998).
The dose response results with Hermissenda were con-
gruous with the published data for several model systems
(Favit et al., 1998; Wender et al., 1998; Etcheberrigaray et
al., 2004; Scioletti et al., 2004; Alkon et al., 2005). Sub-
nanogram concentrations of bryostatin administered before
paired associative conditioning up-regulated PKC activity,
and specifically for Hermissenda, enhanced both acquisition
and retention initiated by suboptimal paired CS/US training
regimes. However, dosages of bryostatin exceeding 1.0
ng/ml were sufficiently high to cause PKC down-regulation,
and there was no recall of any acquired learned behavior
(Table 2). This down-regulation phenomenon has been re-
ported in other neuronal systems and has been associated
with the ubiquitin-proteasome system and apoptosis (Burry,
1998; Vrana and Grant, 2001). Importantly, bryostatin-ex-
posed control animals exhibited no deviations from the
normal expected behavior of naive animals; all behavioral
modifications were specific to animals exposed to the asso-
ciative training regimes.
Of significance was the transition, induced by the addi-
tion of bryostatin, for 2-TE conditioning from short-term
memory (STM) to a long-term memory (LTM) lasting
nearly 24 h. Typically this suboptimal training regime pro-
duced only STM lasting about 7 min (Table 2; Fig. 1). This
long-term enhancement was even more dramatic for 4- and
6-TE regimes in which STM was extended by bryostatin to
full, consolidated memory (CM) lasting for many days;
comparable in numbers to the positive standard of 9-TEs
(Figs. 1–2) (Epstein et al., 2000, 2003, 2004). The blockade
of bryostatin-enhanced training effects initiated when ani-
somycin, an inhibitor of protein translation, was applied
immediately post-training, indicated that bryostatin’s en-
hancement to CM formation required the synthesis of new
protein. These anisomycin results concur with those pub-
lished earlier for Hermissenda (Epstein et al., 2003). Al-
though the exact time-window of the synthesis was not
investigated here, it is contemplated for follow-up studies.
Table 4
Long-lasting depolarization (LLD) data obtained from Hermissenda
photoreceptors under various control (NSW alone) and bryostatin-
administered, associative training conditions
Experimental conditions1 LLD (s) SEM Animals tested
NSW Control: 4-TEs 23.05 2.48 21
Bryostatin (0.25 ng/ml): 4-TEs 54.67 0.72 12
NSW Control: 6-TEs 18.50 1.64 12
Bryostatin (0.25 ng/ml): 6-TEs 49.17 1.11 6
NSW Control: 9-TEs 55.42 0.40 12
Bryostatin (0.25 ng/ml): 9-TEs 52.61 1.26 18
1 Animals received either 4-, 6- or 9-paired conditioned stimulus/uncon-
ditioned stimulus training events (TEs) at 1-min inter-trial intervals. NSW,
natural seawater.
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A regimented, post-training schedule of anisomycin admin-
istration, alone or in conjunction with the PKC inhibitor
Ro-32 (see below), would yield the desired data. It should
also be noted that Hermissenda can be preconditioned, or
primed, for enhanced memory acquisition and recall by
administering bryostatin on 3 successive days prior to train-
ing. Under those conditions, anisomycin had no effect when
applied immediately after suboptimal training (Alkon et al.,
2005). The protein synthesis required for long-term reten-
tion and recall was initiated by bryostatin and completed
prior to training. As a result, the associative conditioning
putatively needed only to transform the training stimuli into
CM.
Use of the specific PKC inhibitor Ro-32 (Ro-0432; bisin-
Figure 8. Enhanced effects of bryostatin in producing a light-induced, long-lasting depolarization (LLD)
response (measured from sharp-electrode intracellular electrophysiologic recordings) in the B-photoreceptors of
associative conditioned Hermissenda. (A) In NSW (natural seawater) control animals, LLDs were produced only with
9 training events (TEs) (4-, 6- vs. 9-TEs: P  0.001). However, bryostatin produced significant LLDs with 4- and
6-TEs, equal to 9-TEs. (B) Representative electrophysiologic records from animals that had received 6-TEs with or
without bryostatin (0.25 ng/ml), plus 9-TE positive controls (n  12; Student’s t comparisons, P  0.001).
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dolylmaleimide-XI, Bis-XI) confirmed the hypothesis that
bryostatin-enhanced CM occurred through PKC activation
(Burry, 1998; Alkon et al., 2005). Due to the specificity of
Ro-32, it can be stated conclusively that PKC- was the
predominant isoform affected (a 10-fold selectivity; Wilkin-
son et al., 1993). Further, the experiments indicated that
PKC activation could be initiated either before training by
bryostatin itself, or synergistically if applied immediately
after paired training. Ro-32 inhibited CM only if it was
applied before training (i.e., purely associative-condition-
ing-induced PKC activation) or bryostatin exposure. Post-
training or post-bryostatin administration of Ro-32 had no
inhibitory effects. The non-effective PKC inhibitor Bis-V
served as an effective negative control.
The increased levels of bryostatin-induced calexcitin
were consistent with those of initial bryostatin studies (Scio-
letti et al., 2004) and with levels induced solely by associa-
tive conditioning (Kuzirian et al., 2001, 2003; Borley et al.,
2002). This study’s data, however, indicated that bryostatin
acting through PKC activation could induce calexcitin lev-
els to rise irrespective of the training paradigm (Figs. 5, 6A,
B; 7). Bryostatin-enhanced calexcitin levels in naive ani-
mals were comparable to those in training conditions that
generated CM (i.e., 9-paired TEs). Four random CS/US
stimuli plus bryostatin apparently down-regulated the sys-
tem, because the levels of calexcitin only doubled. The
random levels were comparable to those seen for STM
activation or to the declining levels exhibited by (4–24 h)
post-trained animals. This latter situation of declining levels
would reflect down-regulated conditions brought about by a
triggered ubiquitin-proteasome pathway, as recently re-
ported by Alkon et al. (2005). It can be concluded on the
basis of the behavioral data and the calexcitin intensity
levels obtained, that full acquisition of learned behavior and
its demonstrated recall in the presence of bryostatin de-
pended upon the nature of the stimulus presentation regimes
used (paired vs. random). Learned acquisition and its recall
required paired CS/US stimuli. Random presentations, even
though accompanied by enhanced calexcitin levels, were
insufficient to modify the animal’s behavior. Additionally,
the actual length of memory retention induced by bryostatin
was again governed by the quality and number of training
events presented: e.g., 2-paired TEs plus bryostatin-en-
hanced STM to the LTM state of about 20 h; 4- and 6-paired
TEs augmented conditions that generated true CM lasting
many days. It can also be stated that the temporal rise in
calexcitin was transient. Calexcitin reached its highest level
within 40–60 min post-training, and remained elevated
until 200 min. It then decreased rapidly to about half that
level by 240 min (Kuzirian et al., 2003), and remained at
that level until returning to baseline by 48 h. Thus, it
appeared that the induction and stabilization of CM that was
dependent upon sustained calexcitin levels was completed
within 48 h.
In Hermissenda, the characteristic biophysical change
generated by 9-paired TEs and the subsequent formation of
CM has long been associated with an LLD in the B-photo-
receptors, as revealed by a single light flash (Crow and
Alkon, 1974; Alkon, 1980; Lederhendler et al., 1986). Un-
der all conditions in this study when bryostatin was present
and positive behavioral acquisition was obtained, a distinct
LLD was demonstrable in the B-photoreceptors. The dura-
tion of the experimental LLDs recorded was statistically the
same for all conditions that produced CM, whether 9-TEs,
or bryostatin-enhanced, suboptimal training conditions (4-,
6-TEs). Physiologically, according to published reports, this
LLD was produced by increased PKC activation coupled
with calexcitin activation and its suppression of, and reduc-
tion in, the outward K currents (IA; IK-Ca), and the release
of Ca2 from internal stores (Farley et al., 1983; Farley and
Auberbach, 1986; Alkon, 1989; Matzel et al., 1992; Saka-
kibara et al., 1993; Alkon et al., 1998). Thus, the acquisition
of CM generated by bryostatin administered in conjunction
with suboptimal training conditions sufficiently mimics the
initial biophysical conditions produced by 9-paired training
regimes with respect to the biophysics of LLD induction.
Toward the question of what stages of memory formation
and recall are affected by bryostatin, the following points
are discussed. The most probable events affected by bryo-
statin-enhanced memory in Hermissenda are those associ-
ated with acquisition and consolidation. Studies on condi-
tioned taste aversion memory conducted with highly
specific PKC inhibitors have revealed that in rats, PKC
activation dominates the processes involved with memory
acquisition (Bielavska and Krivanek, 1994; Krivanek, 1997;
Sacchetti and Bielavska, 1998). Similar results from studies
using chicks were reported by Serrano et al. (1995). The
authors, using the highly specific PKC inhibitor cheleryth-
rine, reported that PKC activation must occur temporally
very near the training events, but that the height of PKC
activity and LTM consolidation appeared only after 60 min.
PKC involvement in memory consolidation and retention
has also been reported for mice (Mathis et al., 1992; Sato et
al., 2004). Like Hermissenda, conditioned rats showed an
immediate translocation of cytosolic PKC to the membrane
that was later followed by a rise in cytosolic levels (but not
membrane-activated PKC) after acquisition (Krivanek,
1997). Krivanek’s results taken together with the results of
Serrano et al. (1995) appear to be mimicked by the time
course of calexcitin increases reported here. To induce the
enhanced memory, bryostatin must be applied either imme-
diately before or after paired-training conditions. To inhibit
the enhancing effects of bryostatin, Ro-32 must precede
training or bryostatin administration. To inhibit protein syn-
thesis, anisomycin must also be applied immediately after
PKC activation. Calexcitin rose to its highest level within
40–60 min post-training and remained high until 200 min.
Epstein et al. (2000, 2003) reported that an initial LTM was
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established 60 min post-training, and that CM was present at
240 min. This CM formation followed a period of DNA
transcription that ended at 180 min and protein translation
that was completed by 220 min. Bryostatin’s induction of
biophysical changes reflected in the generation of LLD also
had to occur before or immediately after training. Together,
all these results lead to the conclusion that bryostatin ini-
tially enhances memory acquisition and likely contributes to
its transition from STM to CM. Indeed, the speculation by
Alkon et al. (2005) that the de novo protein synthesis
(including that of calexcitin) induced by bryostatin exposure
on consecutive days prior to training supports the assump-
tions that PKC activation is involved with memory acqui-
sition and transition. Critical memory proteins were pro-
duced by activated PKC and were immediately available
following training to acquire and store that memory long-
term.
Memory retrieval has not been reported to involve PKC
in murine systems (Mathis et al., 1992; Sacchetti and
Bielavska, 1998). Sato et al. (2004) hypothesized that in
mice, memory retrieval most likely occurs via the phospho-
lipase C/inositol triphosphate pathway, leading to greater
Ca2 release from internal stores and PKA activation by
cAMP. Co-activation of PKA and PKC has been reported in
vertebrate and invertebrate memory systems, principally
involving modulation of synapses, receptors, and channel
activation (Byrne and Kandel, 1996; Li et al., 2002; Millan
et al., 2003). It has been reported for Hermissenda that PKA
modulates synaptic facilitation between the vestibular hair
cells and photoreceptors (Tamse et al., 2003). Thus, the
roles PKC and PKA may play in the processes of memory
retrieval are accessible for study in this model system.
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